Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/152682
COMPARTIR / EXPORTAR:
logo share SHARE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Invitar a revisión por pares abierta
Título

Dream-modulators for dreaming of novel drugs for neurodegenerative diseases

AutorCercós, Pilar CSIC; Peraza, Diego A. CSIC ORCID; Prieto, Ángela CSIC; González, Teresa CSIC ORCID; Mellström, Britt CSIC; García-López, M. Teresa CSIC ; Herranz, Rosario CSIC ORCID; Martín-Martínez, Mercedes CSIC ORCID; Valenzuela, Carmen CSIC ORCID CVN; Naranjo, José Ramón CSIC ORCID; Gutiérrez-Rodríguez, Marta CSIC ORCID
Fecha de publicación2015
CitaciónSIMCC 2015
ResumenAltered neuronal calcium homeostasis and early compensatory changes in transcriptional programs are common features of many neurodegenerative pathologies including Alzheimer's disease, Down syndrome and Huntington's disease. DREAM (Downstream Regulatory Element Antagonist Modulator, also known as calsenilin or KChIP-3 (potassium channel interacting protein-3), is a multifunctional calcium binding protein that controls the expression level and/or the activity of several proteins related to calcium homeostasis, neuronal excitability and neuronal survival. This protein is widely expressed in the brain and, depending on the cell type and physiological conditions, shows multiple subcellular localizations, in the nucleus, cytosol or cell membrane. The interest in DREAM is based on its key role in the regulation of intracellular calcium levels. As a calcium-dependent transcriptional repressor, DREAM is a master regulator of activity-dependent gene expression and controls genes important for calcium homeostasis. As an auxiliary protein in the plasma membrane, DREAM interacts with and regulates the gating of Kv4 potassium channels, L- and T-type voltage-dependent calcium channels and NMDA receptors. These findings suggest that DREAM could be a novel and versatile target for therapeutic intervention in neurodegeneration and that molecules able to bind to DREAM and modulate its physiological functions could be candidates for drugs to treat neurodegenerative diseases. Moreover, up to now, only two DREAMbinding molecules have been identified. In this communication we report the rational design and the synthesis of novel DREAM-binding molecules and their effects on the modulation of DREAM/protein interactions.
DescripciónResumen del póster presentado al Spanish-Italian Medicinal Chemistry Congress, celebrado en Barcelona (España) del 12 al 15 de julio de 2015.
URIhttp://hdl.handle.net/10261/152682
Aparece en las colecciones: (IQM) Comunicaciones congresos
(CNB) Comunicaciones congresos
(IIBM) Comunicaciones congresos




Ficheros en este ítem:
Fichero Descripción Tamaño Formato
accesoRestringido.pdf15,38 kBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo

CORE Recommender

Page view(s)

314
checked on 18-mar-2024

Download(s)

41
checked on 18-mar-2024

Google ScholarTM

Check


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.